Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts. Show more

Location: 490 Arsenal Way, Watertown, MA, 02472, United States | Website: https://tectonictx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

305.5M

52 Wk Range

$13.70 - $61.07

Previous Close

$16.32

Open

$16.40

Volume

1,411,080

Day Range

$15.34 - $18.55

Enterprise Value

19.57M

Cash

287.4M

Avg Qtr Burn

-16.06M

Insider Ownership

38.21%

Institutional Own.

65.03%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.